Introduction
Multiple genetic alterations in the development of human adult gliomas have been described in detail. These alterations include mutations of the TP53 genes (Mashiyama et al., 1991) , homozygous deletion of the INK4A/MTS1 and INK4B/MTS2 genes (Kamb et al., 1994) , inactivation of the PTEN1 gene Steck et al., 1997) , ampli®cation of the EGFR, MDM2, PDGFR, CDK4 and/or cyclin D3 genes (He et al., 1994; Hunter et al., 1995; Kumabe et al., 1992; Sonoda et al., 1995b; Kuchiki et al., 2000) as well as frequent loss of chromosomal loci on 9p, 10, 11q, 13q, 17p, 19q , and 22q (Fults et al., 1990; Collins and James, 1993; Lang et al., 1994; Sonoda et al., 1995a Sonoda et al., , 1996 .
Two distinct oncogenic pathways, chromosomal aberrations and microsatellite instability (MSI), were initially demonstrated in colon cancers, where the target genes and mutational spectra involved in each cascade were dierent (Ionov et al., 1993) . For example, mutational inactivation of the APC and TP53 genes is often associated with chromosomal aberrations in colon cancers (Kinzler and Vogelstein, 1996) . In contrast, slippage mutations of the TGFb RII and BAX genes at their mononucleotide repeat sequences have been detected almost exclusively in colon cancers with MSI (Markowitz et al., 1995; Rampino et al., 1997) . Deletion or insertion of one to several base pairs within the microsatellite sequences of the IGFIIR, E2F4 or PTEN1 gene was also reported in colorectal cancers or endometrial cancers with MSI (Rampino, et al., 1997; Yoshitaka et al., 1996; Kong et al, 1997) .
In gliomas associated with Turcot's syndrome that shows an extensive MSI, germline mutations of the mismatch repair (MMR) genes, hMLH1, hPMS2 or hMSH2 have been reported (Hamilton et al., 1995; Miyaki et al., 1997; Leung et al., 1998) . These ®ndings indicate that MSI are also involved in development of some gliomas. To clarify the involvement of MSI in human gliomas, we examined DNA from 80 tumors and found aberrations of the hMLH1 gene in two gliomas with MSI.
Results

Microsatellite instability in human gliomas
Microsatellite sequences with two mono-, 20 di-, one tri-and one tetra-nucleotide microsatellite repeating units in DNAs from 80 gliomas were analysed. These tumors were from six, eight and 66 patients with onset in their teens, twenties, and older than 30 years, respectively. MSI was found in two teenage onset gliomas (patients 114 and 136). Aberrations were observed at 21 of 24 (88%) microsatellite loci tested in both cases. The changes at the D10S594 and D10S1664 are shown in Figure 1 . Thus these two tumors could be classi®ed as high MSI (MSI-H) tumors (Dietmaier et al., 1997) . Patient 136 had resection of glioblastoma and colon cancer at the age of 16, and was diagnosed as having Turcot's syndrome. His father, grandfather, an uncle and an aunt also suered from colon cancer. On the other hand, patient 114 had neither a family history nor a previous personal history of malignancy. None of the other 78 gliomas showed any MSI at the 24 loci analysed and were classi®ed as microsatellite stable (MSS) tumors.
The PTEN1 gene as the target for mutation in gliomas with and without MSI.
To know genes which could serve as the targets for mutation in MSI-H gliomas, aberrations of genes with microsatellite sequences, such as the TGFbRII (10 adenines), BAX (8 guanines), IGFIIR (6 guanines), PTEN1 (5 adenines) and E2F4 (13 AGC repeats) genes, were examined in tumors from patient 114 and 136. Among the ®ve genes analysed, alteration of microsatellite sequences was observed in the PTEN1 gene in tumors from patient 114. As shown in Figure  2a , SSCP analysis revealed mobility shift of DNA fragment carrying exon 3 of the gene with ®ve continuous adenine residues, while the intensity of the band corresponding to normal DNA was decreased, suggesting the absence of wild-type allele. Nucleotide sequence analyses of the DNA fragment showing the mobility shift revealed an in-frame deletion of 3 bp within the 5-adenine repeat sequence ( Figure 2B ). No other microsatellite alterations were observed in the genes analysed in DNAs from tumors 114 and 136.
Finding of the mutation of the PTEN1 gene in the A stretch region prompted us to analyse alterations of the gene in 78 gliomas without MSI. PCR-SSCP and sequencing analyses of exons 1 ± 9, as well as their anking sequences of the gene, revealed single-base substitutions in ®ve tumors and deletions of four nucleotides in two tumors. All of the PTEN1 mutations in these tumors were associated with LOH of the PTEN1 locus (Table 1 ). (Steck et al., 1997) . (b) Sequences of the DNA fragments containing exon 3 and their anking sequences were determined with a cycle-sequencing kit using 32 P-labeled primers Germline mutation of the hMLH1 gene DNA fragments containing exons 1 ± 19 of the hMLH1 gene as well as their¯anking sequences from lymphocyte DNA of patients 114 and 136 were ampli®ed by PCR and subjected to SSCP analysis. Aberrant signals were detected in DNA fragment from exon 1 of lymphocyte DNA from patient 136. DNA sequencing analysis of this fragment revealed a C to G transversion at the second base of the 29th codon in one of the alleles ( Figure 3a ). This mutation produced a cryptic splice donor site resulting in the expression of two aberrant transcripts in nearly equal amounts. Nucleotide sequence analysis of RT ± PCR products a b
Promoter methylation of the hMLH1 gene and PTEN1 mutation in gliomas M Kanamori et al revealed that C residue at the ®rst base of codon 29 in exon 1 was joined to the ®rst T residue of exon 2 in transcript 1 or to the sixth A residue of exon 2 in transcript 2 (Figure 3b ). Thus transcript 1 contained a frameshift resulting in the synthesis of a truncated polypeptide of 29 amino acids, while transcript 2 had an in-frame deletion of the 29th to 40th codons (12 amino acids) (Figure 3c ). No mutations were observed in the coding sequences of the other allele in the glioblastoma in this patient. However, no wild-type transcript of the gene was detected by RT ± PCR analysis, indicating that the expression of the normal allele was suppressed in the tumor. No mutations of the other MMR genes, hMSH2, hPMS2, hPMS1, hMSH3 and hMSH6 were detected in lymphocyte DNA from this patient. Patient 114 did not have germline mutations in the coding sequence of either hMLH1 or hMSH2 gene, as revealed by PCR ± SSCP analysis of all the exons and their¯anking sequences of genomic DNA, as well as by sequence analysis of RT ± PCR products of RNA from the lymphocytes. Moreover, no alterations were detected in the other MMR genes analysed by genomic PCR ± SSCP or RT ± PCR ± SSCP analyses, suggesting that this patient was not a proband of Turcot's syndrome. However, in the tumor of this patient, only a low level of the hMLH1 cDNA product was detected compared with that observed in normal brain tissue of another individual (less than 20%) (Figure 4a,b) . Taking the inevitable contamination by normal cells in the tumor tissues into consideration, it was likely that hMLH1 expression was mostly lost in the tumor.
Inactivation of the hMLH1 gene by promoter methylation
Expression of the hMLH1 gene was reported to be suppressed by methylation at CpG sites in the promoter region of the gene in some colon cancers (Kane et al, 1997; Herman et al., 1998; Veigl et al., 1998) . To know whether suppression of expression of the normal hMLH1 allele in the tumor of patient 136 and also in that of patient 114 is due to methylation of the promoter region, the DNAs obtained from lymphocytes and tumor tissues of the two patients, together with those from 20 tumors with MSS, were digested with methylation-sensitive or insensitive restriction endonucleases, HpaII or MspI, respectively. Then digested DNAs were subjected to PCR as the template for ampli®cation of an 829-bp DNA fragment containing the regions of promoter and exon 1 of the hMLH1 gene (Figure 5a ). As shown in Figure 5b , the DNA fragment ampli®ed from the corresponding region was detected in tumor DNA but not in normal DNA in both of patients 136 and 114 after digestion with HpaII. On the other hand, as shown in patient 107 representatively, no fragments were obtained from DNAs of 20 tumors with MSS as well as those from corresponding normal tissues after digestion with Hpall.
The 829-bp DNA fragment ampli®ed from the wild type hMLH1 gene carried the nucleotide sequence AGCT at the 28th and 29th codon in exon 1, while that ampli®ed from mutant DNA from patient 136 contained the sequence AGGT. Therefore, digestion of the 829-bp fragment from the mutant allele with restriction endonuclease AluI would produce a fragment of 254 bp. On the other hand, the fragment from the normal allele would be segmented into two pieces of 180 bp and 74 bp (Figure 5a ). When DNA fragment of 829 bp ampli®ed from HpaII-treated tumor DNA from patient 136 was digested with AluI, the fragments of 180 bp and 74 bp speci®c to the normal allele but not the fragment of 254 bp speci®c to the mutant allele was observed (Figure 5c ).
These ®ndings suggested that CpG residues in the promoter region of the normal hMLH1 gene was speci®cally methylated in the tumor DNA of patients 136 and 114. In the tumor of patient 136, this methylation could act as the second hit to inactivate the normal hMLH1 gene. In the tumor of patient 114, methylation could be involved in the loss of expression of this gene in total. The absence of a family history of malignancy for patient 114 was consistent with this assumption.
Discussion
The present study on 80 human gliomas con®rmed that MSI was involved in a subset (2/80 tumors) of gliomas. We searched for the inactivation of the MMR genes causing severe MSI in the two gliomas and found a germline mutation and promoter methylation of the hMLH1 gene. Germline mutations of the hMLH1, hPMS2 and hMSH2 genes in lymphocyte DNAs of the patinents with Turcot's syndrome have been demonstrated previously (Hamilton et al., 1995; Miyaki et al., 1997; Leung et al., 1998) .
Methylation at the CpG residues in the promoter sequence and resulting loss of expression of the hMLH1 gene in total were reported in a subset of colon, gastric and lung cancers (Kane et al., 1997; Herman et al., 1998; Cunningham et al., 1998; Leung et al., 1999; Esteller et al., 1999) . Present study showed that epigenetic inactivation of the hMLH1 gene was also involved in a subset of gliomas. Moreover, we demonstrated that the promoter sequence of the wild type hMLH1 gene was selectively methylated in tumor DNA from patient 136 by distinguishing the mutated allele from the wild type allele. Selective silencing of wild type but not mutant alleles of the p16 gene has were digested with AluI and subjected to agarose gel electrophoresis. Fragments of 180 bp (**) and 74 bp (***) were derived from the normal allele, while a 254-bp fragment (*) was derived from the mutant allele. The other six fragments of 316, 147, 57, 33, 15 and 6 bp were derived from other regions of the 829-bp fragments. Fragments shorter than 57 bp cannot be seen in this ®gure also been reported in a colon cancer cell line (Myohanen et al., 1998) . These ®ndings strongly suggest that promoter methylation could act as the second hit to inactivate the hMLH1 gene. Progenitor cells expressing only the mutated hMLH1 gene might be selected during the early development of the glioma from patient 136. On the other hand, both of the hMLH1 alleles appeared to be methylated in the glioma from patient 114. Methylation of both p16 alleles has also been reported in a pancreatic cancer cell line (Schutte et al., 1997) .
Thus, inactivation of the hMLH1 gene was demonstrated to be the primary defects that caused severe MSI in these two tumors. Then the downstream target genes for mutation by MSI in gliomas were analysed. recently reported slippage mutation of the IGFIIR gene in a glioma associated with Turcot' syndrome. Among ®ve known genes carrying microsatellites within their coding sequences, the PTEN1 gene was altered by slippage mutation in tumor 114. This mutation resulted in in-frame deletion of lysine residue at position 62, a tensine homologous domain of PTEN1 protein. In-frame deletion of a single amino acid within the same domain was also reported in a patient of Cowden disease (Nelen et al., 1999) . These ®ndings suggest that in-frame deletion observed in tumor 114 would be an inactivating mutation. PTEN1 mutations were also observed in gliomas without severe MSI, demonstrating that loss of the PTEN1 product could play an important role in tumor formation in both gliomas with and without MSI. Mutation of the PTEN1 gene has also been reported in both MSI-positive and MSI-negative endometrial cancers (Kong et al., 1997) .
In MSI-H tumor 114, deletion of three of ®ve contiguous adenines shown in Figure 2b appeared to be caused by a de®ciency in mismatch repair. On the other hand, distinct spectra of mutations were observed in seven of the 78 tumors without severe MSI: singlenucleotide substitutions in ®ve tumors and deletions of short nucleotide sequences in two tumors. Our previous study revealed that all seven MSS tumors carrying mutated PTEN1 genes were associated with loss of entire chromosome 10 or 10q (Sonoda et al., 1996; Kon et al., 1998) . Since LOH had also occurred on several chromosomes other than 10, chromosomal aberrations might play an important role in the development of these tumors (Mashiyama, et al., 1991; Sonoda et al., 1995a; Kon et al., 1998) . On the other hand, as shown in Table 1 , allelic imbalance was not observed in any chromosomal loci analysed in the two MSI-H tumors. These results suggest that the two glioblastomas from patients 114 and 136 could develop through alternative carcinogenic pathway based on microsatellite instability.
It is noteworthy that MSI was frequently found in teenage onset glioblastomas (WHO grade IV) in the present study, although the number of patients was limited (two of six cases; 33%). Leung et al. also reported that four of 22 malignant gliomas (WHO grade III or IV) with onset at less than 45 years of age, carried germline mutations of the hMLH1 or hMSH2 genes (Leung et al., 1998) . Further detection of this type of tumor and analyses of causative mutations or methylation of the hMLH1 gene as well as other genes involved in MMR should cast new light on the genesis of early onset human glioblastomas.
Materials and methods
Human tissue samples
All glioma specimens were surgically resected and histologically diagnosed according to the WHO brain-tumor scheme (Kleihues et al., 1993) at the Department of Neurosurgery, Tohoku University School of Medicine, Sendai, Japan. Corresponding constitutional DNAs or RNAs were obtained from peripheral blood leukocytes of each patient.
PCR analysis of microsatellite markers
Genomic DNA was extracted by the standard proteinase Kphenol-chloroform method (Blin and Staord, 1976) . DNA fragments were ampli®ed by PCR and subjected to polyacrylamide gel electrophoresis as described previously (Kon et al., 1998) . The 24 microsatellite markers examined were BAT25T, BAT26T, D2S123, D5S346, D10S189, D10S191, D10S507, D10S509, D10S547, D10S552, D10S558, D10S585, D10S591, D10S594, D10S602, D10S1136, D10S1649, D10S1653, D10S1664, D10S1691, D10S1713, D10S1714, D10S1751 and D17S250. Primer sequences for the mononucleotide repeats at the TGFb RII, BAX, IGFIIR and E2F4 genes were described by others (Markowitz et al., 1995; Souza et al., 1996; Rampino et al., 1997; Yoshitaka et al., 1996) .
Cloning and sequencing of DNA fragments DNA fragments were ampli®ed from genomic DNA or cDNA by PCR and subcloned using the TA cloning vector pCRII (Invitrogen, Carlsbad, USA). Nucleotide sequences of the cloned fragments were determined using the Thermosequenase cycle sequencing system (Amersham, Cleveland, OH, USA).
Analysis of hMLH1 expression by RT ± PCR
Total cellular RNA was extracted by the guanidinium isothiocyanate method (Chomczynski and Sacchi, 1987) . Aliquots of 1 mg of total cellular RNA were subjected to cDNA synthesis reaction using 200 units of reverse transcriptase (Super Script II; Life Technologies, Inc., Rockville, MD, USA) as described previously . Competitive PCR was carried out using a pair of primers for hMLH1 cDNA (5'-AGTGGCTGGACAGAG-GAAGA-3' and 5'-GATCAGGCAGGTTAGCAAGC-3') and for b-actin cDNA (5'-AGCACTGTGTTGGCGTA-CAG-3' and 5'-AGATCTGGCACCACACCTTC-3'), one of which was labeled with 32 P at the 5'-end. The relative amounts of hMLH1 mRNA were determined by counting the radioactivity of 32 P-labeled fragments using BAS 2000 detection system (Fuji, Tokyo, Japan).
Analysis of methylation status of the hMLH1 promoter region
Genomic DNA was digested with HpaII or MspI, and used as the template for PCR ampli®cation of the 829-bp fragment including the upstream region, exon 1 and a portion of intron 1 of the hMLH1 gene, that contains ®ve HpaII sites. Primer sequences used were 5'-CGCTCGTAGTATTCGTGCTC-3' and 5'-AAGTCGTAGCCCTTAAGTGA-3' (Kane et al., 1997 ). The obtained fragments were then subjected to agarose gel electrophoresis.
PCR ± SSCP and sequencing analyses of the PTEN1 gene Nine DNA fragments of 227 ± 475 base pairs (bp), corresponding to exons 1 ± 9 with their¯anking sequences of the PTEN1 gene, were ampli®ed by PCR and subjected to SSCP analysis (Orita et al, 1989) . The sequences of the primers used were reported previously (Steck et al., 1997) . Abnormal bands detected by SSCP analysis were eluted from the gel (Suzuki et al., 1990) , ampli®ed by PCR and determined the sequences using the Thermosequenase cycle sequencing system (Amersham, Cleveland, OH, USA).
